Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596
Debt
Debt-to-Equity Ratio0.33
Current Ratio2.72
Quick Ratio2.27
Price-To-Earnings
Trailing P/E Ratio22.48
Forward P/E Ratio17.96
P/E Growth1.15
Sales & Book Value
Annual Sales$3.55 billion
Price / Sales7.28
Cash Flow$7.8378 per share
Price / Cash14.80
Book Value$39.81 per share
Price / Book2.91
Profitability
EPS (Most Recent Fiscal Year)$5.16
Net Income$443.30 million
Net Margins-2.68%
Return on Equity15.21%
Return on Assets9.96%
Miscellaneous
Employees2,525
Outstanding Shares222,860,000
Market Cap$26.49 billion
Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions
What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
How will Alexion Pharmaceuticals' stock buyback program work?
Alexion Pharmaceuticals declared that its board has authorized a stock repurchase plan on Sunday, April 9th 2017, which permits the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 3.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.
How were Alexion Pharmaceuticals' earnings last quarter?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced its quarterly earnings data on Thursday, July, 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the Zacks' consensus estimate of $1.49 by $0.58. The biopharmaceutical company earned $1.05 billion during the quarter, compared to analysts' expectations of $976.81 million. Alexion Pharmaceuticals had a positive return on equity of 15.21% and a negative net margin of 2.68%. The firm's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.56 earnings per share. View Alexion Pharmaceuticals' Earnings History.
When is Alexion Pharmaceuticals' next earnings date?
What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?
Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday, July, 26th. The company provided EPS guidance of $7.00-7.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.02. The company issued revenue guidance of $3.98-4.01 billion, compared to the consensus revenue estimate of $4.00 billion.
What price target have analysts set for ALXN?
18 brokers have issued 12-month price targets for Alexion Pharmaceuticals' shares. Their predictions range from $123.00 to $188.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $159.00 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.
What is the consensus analysts' recommendation for Alexion Pharmaceuticals?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.
Who are some of Alexion Pharmaceuticals' key competitors?
Some companies that are related to Alexion Pharmaceuticals include Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY) and Teva Pharmaceutical Industries (TEVA).
Who are Alexion Pharmaceuticals' key executives?
Alexion Pharmaceuticals' management team includes the folowing people:
- Dr. Ludwig N. Hantson, CEO & Director (Age 55)
- Mr. Paul J. Clancy, Exec. VP & CFO (Age 56)
- Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 49)
- Daniel A. Bazarko CPA, Chief Accounting Officer and Sr. VP
- Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 46)
Has Alexion Pharmaceuticals been receiving favorable news coverage?
News headlines about ALXN stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a news and rumor sentiment score of 0.20 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.25 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Alexion Pharmaceuticals.
Who are Alexion Pharmaceuticals' major shareholders?
Alexion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.76%), BlackRock Inc. (7.30%), Jennison Associates LLC (2.70%), Bank of New York Mellon Corp (1.36%), Iridian Asset Management LLC CT (0.67%) and Wells Fargo & Company MN (0.67%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, Edward Miller, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.
Which institutional investors are selling Alexion Pharmaceuticals stock?
ALXN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, Millennium Management LLC, Waddell & Reed Financial Inc., Morgan Stanley, Janus Henderson Group PLC, Connor Clark & Lunn Investment Management Ltd. and Virginia Retirement Systems ET AL. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.
Which institutional investors are buying Alexion Pharmaceuticals stock?
ALXN stock was bought by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Advisors Asset Management Inc., Sound Shore Management Inc. CT, Swedbank, Putnam Investments LLC, Point72 Asset Management L.P., Bessemer Group Inc. and Nomura Holdings Inc.. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.
How do I buy shares of Alexion Pharmaceuticals?
Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alexion Pharmaceuticals' stock price today?
One share of ALXN stock can currently be purchased for approximately $116.00.
How big of a company is Alexion Pharmaceuticals?
Alexion Pharmaceuticals has a market capitalization of $26.49 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.
How can I contact Alexion Pharmaceuticals?
Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]
MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
